Eli Lilly and Hims & Hers Announce Agreement to Expand Access to Obesity Medications

Eli Lilly and Hims & Hers agreed to expand access to Lilly’s FDA-approved obesity medications Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform. Eligible patients with prescriptions from licensed providers can obtain the drugs at the same self-pay prices available to other patients without leaving the platform. The companies disclosed no sales projections or patient adoption targets.